Market Overview
According to the research report, the global minimal residual disease market was valued at USD 1,973.35 million in 2022 and is expected to reach USD 7,131.61 million by 2032 by 2032, to grow at a CAGR of 13.7% during the forecast period.
Minimal Residual Disease refers to the small number of cancer cells that remain in a patient’s body after treatment and may lead to relapse. While conventional imaging and clinical assessment often fail to detect these residual cells, MRD testing employs advanced molecular techniques such as circulating tumor DNA (ctDNA) analysis, next-generation sequencing (NGS), and flow cytometry to identify and quantify them with remarkable precision.
Market Segmentation
The MRD market is segmented based on technology, application, end user, and region.
By Technology:
- Next-Generation Sequencing (NGS)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Digital Droplet PCR (ddPCR)
NGS dominates the market due to its high accuracy and ability to detect a broad range of mutations. Flow cytometry remains widely used, particularly in academic and research settings, while PCR-based platforms are favored for their speed and cost-effectiveness.
By Application:
- Hematologic Malignancies
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma
- Non-Hodgkin’s Lymphoma
- Solid Tumors
- Colorectal Cancer
- Breast Cancer
- Lung Cancer
- Others
Hematologic malignancies account for the largest share due to the widespread use of MRD in leukemia treatment protocols. However, applications in solid tumors are expanding rapidly through ctDNA and liquid biopsy innovations.
By End User:
- Hospitals & Oncology Clinics
- Academic & Research Institutes
- Diagnostic Laboratories
- Pharmaceutical & Biotech Companies
Hospitals and oncology clinics are the primary end users, supported by rising integration of MRD tests into standard treatment workflows. Pharmaceutical companies are increasingly incorporating MRD endpoints in clinical trials to assess drug efficacy.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market
Regional Analysis
The Minimal Residual Disease market spans North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, each with distinct growth trends.
North America
North America leads the global MRD market, accounting for over 40% of total revenue. The region’s dominance is due to a high incidence of cancer, advanced healthcare infrastructure, and a strong presence of key industry players. The U.S. FDA’s supportive regulatory environment and early adoption of molecular diagnostics have further fueled market penetration.
Europe
Europe follows closely, with countries like Germany, France, and the UK investing heavily in genomic medicine. The region is witnessing growing use of MRD testing in clinical trials and national cancer strategies. The European Hematology Association has been instrumental in promoting MRD guidelines.
Asia-Pacific
Asia-Pacific is projected to witness the fastest CAGR, driven by rising cancer burden, improving healthcare access, and increased government spending on genomics research. China and India are emerging as significant markets due to investments in diagnostic infrastructure and collaborations with global biotech firms.
Latin America
Although still in early development stages, Latin America shows potential, especially in Brazil and Mexico. Public-private partnerships and increased awareness of early cancer detection are creating new opportunities.
Middle East & Africa
The market in this region is nascent but growing steadily. Countries like Saudi Arabia, UAE, and South Africa are expanding their oncology care capacities, with a focus on advanced diagnostics.
Key Companies
The MRD market is highly competitive, with several diagnostics giants and innovative biotech startups vying for market share. Mergers, acquisitions, and strategic collaborations are commonplace as companies race to expand assay portfolios and global reach.
Leading Players:
- Natera, Inc.
A pioneer in ctDNA-based MRD testing, Natera’s Signatera™ assay has revolutionized personalized cancer monitoring and is widely used in both solid tumors and hematologic cancers. - Guardant Health
Specializing in liquid biopsies, Guardant’s Guardant Reveal is a key player in the solid tumor MRD space, especially for colorectal and lung cancer monitoring. - Invitae Corporation
Through its acquisition of ArcherDX, Invitae offers NGS-based MRD assays tailored for hematologic malignancies and continues to grow its clinical trial collaborations. - Adaptive Biotechnologies
Adaptive’s clonoSEQ® test is FDA-cleared for MRD detection in multiple myeloma, ALL, and CLL, and is considered a gold standard in the field. - Sysmex Corporation
The Japan-based company is known for its automated flow cytometry systems used in MRD evaluation, with growing penetration in Europe and Asia. - F. Hoffmann-La Roche AG
Roche continues to develop MRD capabilities through its NGS brand, Foundation Medicine, and is integrating these into broader oncology platforms. - Bio-Rad Laboratories, Inc.
A leader in PCR and ddPCR technologies, Bio-Rad provides critical reagents and instruments used in high-sensitivity MRD testing workflows. - QIAGEN N.V.
Through its PCR and NGS platforms, QIAGEN offers comprehensive sample-to-answer solutions for MRD detection in research and clinical settings. - Illumina, Inc.
The global leader in sequencing technologies, Illumina provides platforms powering most commercial NGS-based MRD assays. - Genetron Health
Based in China, Genetron is making strides in MRD testing for liver and lung cancers, with ctDNA assays adapted for the Asia-Pacific market.
Recent Industry Developments
- In 2024, Adaptive Biotechnologies expanded the clonoSEQ® test’s clinical utility by securing new indications for CLL monitoring post-transplant.
- Natera partnered with pharmaceutical firms to integrate MRD as a surrogate endpoint in cancer drug trials, accelerating time to market.
- Guardant Health launched a new AI-driven analytics tool for real-time interpretation of ctDNA MRD results in colorectal cancer.
- Invitae received CE marking for its NGS MRD assay, enabling expansion into the European market.
- Roche acquired a minority stake in a biotech firm specializing in early MRD detection for solid tumors.
Conclusion
The Minimal Residual Disease Market is rapidly transforming the landscape of cancer diagnostics and treatment monitoring. With breakthroughs in ctDNA, NGS, and molecular diagnostics, MRD testing is becoming an integral part of precision oncology.
More Trending Latest Reports By Polaris Market Research:
Voluntary Carbon Credit Market
Hazardous Area Equipment Market
Polytetrafluoroethylene (PTFE) Market
